Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of “Buy” from Analysts

Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) have received a consensus rating of “Buy” from the eight research firms that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $220.00.

A number of analysts have recently commented on KRYS shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. Jefferies Financial Group initiated coverage on shares of Krystal Biotech in a research report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research report on Thursday, February 20th. Citigroup upped their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a research report on Friday, February 28th.

Krystal Biotech Stock Performance

Shares of NASDAQ KRYS opened at $187.15 on Monday. The stock has a market cap of $5.39 billion, a P/E ratio of 62.59 and a beta of 0.87. The firm has a 50 day moving average price of $166.67 and a 200 day moving average price of $173.74. Krystal Biotech has a 52-week low of $141.72 and a 52-week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, February 24th. The company reported $1.52 earnings per share for the quarter, beating analysts’ consensus estimates of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the previous year, the firm posted $0.30 earnings per share. The business’s revenue was up 116.4% on a year-over-year basis. Analysts predict that Krystal Biotech will post 6.14 earnings per share for the current fiscal year.

Insider Activity at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at $260,233,178.69. This represents a 1.68 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CAO Kathryn Romano sold 750 shares of the stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total transaction of $131,415.00. Following the completion of the transaction, the chief accounting officer now directly owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This trade represents a 5.62 % decrease in their position. The disclosure for this sale can be found here. 14.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in KRYS. Crossmark Global Holdings Inc. lifted its holdings in shares of Krystal Biotech by 25.8% in the third quarter. Crossmark Global Holdings Inc. now owns 2,186 shares of the company’s stock worth $398,000 after acquiring an additional 449 shares during the last quarter. Prime Capital Investment Advisors LLC raised its holdings in Krystal Biotech by 93.1% in the 3rd quarter. Prime Capital Investment Advisors LLC now owns 2,591 shares of the company’s stock valued at $472,000 after buying an additional 1,249 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Krystal Biotech in the 3rd quarter valued at approximately $235,000. KBC Group NV raised its holdings in Krystal Biotech by 25.9% in the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock valued at $117,000 after buying an additional 132 shares during the last quarter. Finally, Huntington National Bank raised its holdings in Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).